KT-621: Compelling Preclinical Profile
Preclinical Package Suggests Potential for Dupilumab-like Activity in a Pill

                                                                   Full Inhibition of IL-4/IL-13           Excellent Preclinical
                        Exquisite          Robust Degradation
                                                                    Pathways, More Potent                 Activity Comparable or
                       Selectivity        in Relevant Cell Types
                                                                         than Dupilumab                   Superior to Dupilumab
                                                                                                                Lung Remodeling
                                            STAT6 Degradation in    IL-4 Induced TARC Release in
                                                                                                              Goblet Cell Metaplasia
                                               Immune Cells                 Human PBMC
                                                                                                                 in HDM Model1
                  4




-Log10(p-Value)
                  2




                  0

                      -2      0      2
                      Log2(Fold-Change)




    Favorable safety profile: well-tolerated in multiple preclinical species and safety studies at
    concentrations 40-fold above efficacious dose with up to 4 months of dosing
                                                                                 visit Kymeraâ€™s website                                56
